Article
Prediction of acute myeloid leukaemia risk in healthy individuals.
Nature - 1 Jul 2018
Abelson Sagi, Collord Grace, Ng Stanley W K, Weissbrod Omer, Mendelson Cohen Netta, Niemeyer Elisabeth, Barda Noam, Zuzarte Philip C, Heisler Lawrence, Sundaravadanam Yogi, Luben Robert, Hayat Shabina, Wang Ting Ting, Zhao Zhen, Cirlan Iulia, Pugh Trevor J, Soave David, Ng Karen, Latimer Calli, Hardy Claire, Raine Keiran, Jones David, Hoult Diana, Britten Abigail, McPherson John D, Johansson Mattias, Mbabaali Faridah, Eagles Jenna, Miller Jessica K, Pasternack Danielle, Timms Lee, Krzyzanowski Paul, Awadalla Philip, Costa Rui, Segal Eran, Bratman Scott V, Beer Philip, Behjati Sam, Martincorena Inigo, Wang Jean C Y, Bowles Kristian M, Quirós J Ramón, Karakatsani Anna, La Vecchia Carlo, Trichopoulou Antonia, Salamanca-Fernández Elena, Huerta José M, Barricarte Aurelio, Travis Ruth C, Tumino Rosario, Masala Giovanna, Boeing Heiner, Panico Salvatore, Kaaks Rudolf, Krämer Alwin, Sieri Sabina, Riboli Elio, Vineis Paolo, Foll Matthieu, McKay James, Polidoro Silvia, Sala Núria, Khaw Kay-Tee, Vermeulen Roel, Campbell Peter J, Papaemmanuil Elli, Minden Mark D, Tanay Amos, Balicer Ran D, Wareham Nicholas J, Gerstung Moritz, Dick John E, Brennan Paul, Vassiliou George S, Shlush Liran I
Abstract excerpt
The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure1. The onset of such de novo AML cases is typically preceded by the accumulation of somatic mutations in preleukaemic haematopoietic stem and progenitor cells...
Read the complete abstract on PubMed